-
FTC sets closed-door meeting ahead of next week’s Walgreens-Rite Aid merger deadline
WASHINGTON — The Federal Trade Commission’s is set to hold a closed-door meeting on Thursday. The meeting comes in the lead-up to the Jul. 7 deadline by which the regulatory agency has to approve or file suit to block the Walgreens-Rite Aid merger.
-
FDA approves Genentech’s Rituxan Hycela
SILVER SPRING, Md. — The Food and Drug Administration recently approved a new treatment option for patients with three of the most common types of blood cancer. Genentech’s Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection was approved Thursday to treat adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma and previously untreated and previously treated chronic lymphocytic leukemia.XThis ad will auto-close in 10 seconds